Pharmacogenetics of Drug-Drug Interaction (DDI) and Drug-Drug-Gene-Interaction (DDGI): a Systematic Review on CYP2C9, CYP2C19, and CYP2D6

Didik, Setiawan (2018) Pharmacogenetics of Drug-Drug Interaction (DDI) and Drug-Drug-Gene-Interaction (DDGI): a Systematic Review on CYP2C9, CYP2C19, and CYP2D6. ARTIKEL JURNAL.

	Text (Similiarity) 06. Pharmacogenetics of drug–drug interaction and drug–drug–gene interaction Plagramme.pdf Download (732kB)
	Text (Peer Review) 07.Pharmacogenetics of drug–drug interaction and drug–drug–gene interaction a systematic review on CYP2C9, CYP2C19 and CYP2D6.pdf Download (1MB)

Abstract

Currently, most guidelines on drug-drug interaction (DDI) neither consider the potential effect of genetic polymorphism in the strength of the interaction nor do they account for the complex interaction caused by the combination of DDI and drug-gene-interaction (DGI) where there are multiple biotransformation pathways, which is referred to as drug-drug-gene-interaction (DDGI). In this systematic review we report the impact of pharmacogenetics on DDI and DDGI in which three major drug-metabolizing enzymes - CYP2C9, CYP2C19, and CYP2D6 - are central. We observed that several DDI and DDGI are highly gene-dependent, leading to a different magnitude of interaction. Precision drug therapy should take pharmacogenetics into account when drug interactions in clinical practice are expected.

Actions (login required)

View Item